Genetic landscape of stage II melanoma identifies CBL as a new driver gene and prognostic biomarker. Lindner ES, Admard J, Demidov G, Armeanu-Ebinger S, et al. Br J Cancer 2026 Apr 9. doi: 10.1038/s41416-026-03394.

Read + Share

Amedeo Smart

Independent Medical Education

Lindner ES, Admard J, Demidov G, Armeanu-Ebinger S, et al. Genetic landscape of stage II melanoma identifies CBL as a new driver gene and prognostic biomarker. Br J Cancer 2026 Apr 9. doi: 10.1038/s41416-026-03394.
PMID: 41957139